Yuchen Zhang

5PUBLICATIONS
23CO-AUTHORS
Molecular targetsTumour immunologyCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jun 15, 2026
Liposomal mitoxantrone plus tislelizumab in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma: a phase 1b/2 trial.

|May 30, 2026
Treatment Patterns and Clinical Outcomes After Immunotherapy Failure in Patients With Natural Killer/T-Cell Lymphoma.

|Mar 30, 2026
LM-101, an Anti-SIRPĪ± Antibody, in Patients with Relapsed/Refractory Lymphoma and Advanced Head and Neck Cancer: An Open-Label, Multicenter, Phase I Trial.

Jun Cai, Baitian Zhao, Dongmei Ji

|Oct 07, 2021
Combination of PD-1 inhibitor with GVD (gemcitabine, vinorelbine, liposomal doxorubicin) versus GVD regimen as second-line therapy for relapsed/refractory classical Hodgkin lymphoma.

Yu-Chen Zhang, Jin-Ni Wang, Shu-Yun Ma

|May 04, 2021
A prognostic immune risk score for diffuse large B-cell lymphoma.

Shu-Yun Ma, Xiao-Peng Tian, Jun Cai

Pageof 1

Frequent Collaborators

4 joint publications

Qingqing Cai

2 joint publications

Jun Cai

2 joint publications

Liang Wang

2 joint publications

Man Nie